Renal toxicity during cancer treatment with angiogenesis inhibitors
Completed
- Conditions
- Podocyturia as a possible early marker of renal toxicity during angiogenesis inhibition
- Registration Number
- NL-OMON29589
- Lead Sponsor
- Dr. M.H.W. Kappers, Amphia hospital Breda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Patients with malignancy treated with an anti-VEGF monoclonal antibody or receptor tyrosine kinase inhibitor (RTKI) + chemotherapy
- Patients treated with chemotherapy alone (without an anti-VEGF monoclonal antibody or RTKI) = control group 1
Exclusion Criteria
- Healthy controls (control group 2) with abnormal kidney function and/or proteinuria (protein-to-creatinine ratio > 45 mg/mmol or albumin-to-creatinine ratio > 30 mg/mmol)
- Known renal insufficiency (MDRD < 60 ml/min) in patients with malignancy and/or proteinuria (protein-to-creatinine ratio > 45 mg/mmol or albumin-to-creatinine ratio > 30 mg/mmol) if this latter has been previously reported
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of podocyturia during treatment with an angiogenesis inhibitor
- Secondary Outcome Measures
Name Time Method the correlation between podocyturia and proteinuria, the correlation between podocyturia and renal function, the correlation between podocyturia and blood pressure, the effect of angiotensin converting enzyme inhibitors (ACEi) on podocyturia